NASDAQ:AERI - Aerie Pharmaceuticals Stock Price, Price Target & More

$53.65 -0.30 (-0.56 %)
(As of 04/22/2018 06:24 AM ET)
Previous Close$53.65
Today's Range$53.40 - $54.40
52-Week Range$38.14 - $66.60
Volume144,478 shs
Average Volume270,334 shs
Market Capitalization$2.12 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.95

About Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals logoAerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for AERI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AERI
CUSIPN/A
Phone919-237-5300

Debt

Debt-to-Equity Ratio0.91%
Current Ratio10.09%
Quick Ratio10.09%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.60 per share
Price / Book14.90

Profitability

EPS (Most Recent Fiscal Year)($3.37)
Net Income$-145,100,000.00
Net MarginsN/A
Return on Equity-97.23%
Return on Assets-47.73%

Miscellaneous

Employees160
Outstanding Shares39,490,000

How to Become a New Pot Stock Millionaire

Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals (NASDAQ:AERI) released its earnings results on Wednesday, February, 28th. The company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.21) by $0.17. View Aerie Pharmaceuticals' Earnings History.

What price target have analysts set for AERI?

11 brokers have issued twelve-month price targets for Aerie Pharmaceuticals' stock. Their forecasts range from $68.00 to $100.00. On average, they anticipate Aerie Pharmaceuticals' stock price to reach $79.9091 in the next twelve months. View Analyst Ratings for Aerie Pharmaceuticals.

What are Wall Street analysts saying about Aerie Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Aerie received a significant boost with the recent approval of lead drug Rhopressa. The approval came ahead of the PDUFA date. Meanwhile, Aerie is also evaluating Roclatan, a once-daily, quadruple action fixed-dose combination of Rhopressa and Xalatan. Aerie’s shares have outperformed the industry in the last  twelve months. However, Rhopressa faces stiff competition from established branded and generic pharmaceutical companies, such as Novartis’ Simbrinza and Travtan, and Allergan’s Lumigan, as well as other smaller biotechnology and pharmaceutical companies. Valeant Pharmaceutical’s Vyzulta is also approved for open-angle glaucoma or ocular hypertension. Rhopressa will face a tough time in gaining market share due to competition from these products. Any approval delays for Roclatan like Rhopressa will be detrimental to the company's growth prospects." (4/17/2018)
  • 2. Mizuho analysts commented, "We hosted investor meetings with Aerie management on January 25. Key points that were discussed: 1) Recent capital raise; 2) Readiness for commercialization; and 3) 2018 guidance. We feel confident in management’s abilities with respect to commercial execution as well as maximization of shareholder value should a take-out happen." (1/29/2018)

Who are some of Aerie Pharmaceuticals' key competitors?

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the folowing people:
  • Dr. Vincente J. Anido Jr., Ph.D., Chairman & CEO (Age 65)
  • Mr. Thomas A. Mitro, Pres & COO (Age 60)
  • Mr. Richard James Rubino CPA, CFO & Sec. (Age 60)
  • Dr. Casey C. Kopczynski Ph.D., Co-Founder & Chief Scientific Officer (Age 57)
  • Ms. Jessica Crespo CPA, Director of Accounting

Has Aerie Pharmaceuticals been receiving favorable news coverage?

News headlines about AERI stock have been trending positive on Sunday, Accern reports. The research group scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aerie Pharmaceuticals earned a news sentiment score of 0.44 on Accern's scale. They also gave media stories about the company an impact score of 45.71 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $53.65.

How big of a company is Aerie Pharmaceuticals?

Aerie Pharmaceuticals has a market capitalization of $2.12 billion. The company earns $-145,100,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Aerie Pharmaceuticals employs 160 workers across the globe.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]


MarketBeat Community Rating for Aerie Pharmaceuticals (AERI)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  466 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  611
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe AERI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AERI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aerie Pharmaceuticals (NASDAQ:AERI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Aerie Pharmaceuticals in the last 12 months. Their average twelve-month price target is $79.9091, suggesting that the stock has a possible upside of 48.95%. The high price target for AERI is $100.00 and the low price target for AERI is $68.00. There are currently 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.922.92
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $79.9091$79.9091$72.4615$70.00
Price Target Upside: 48.95% upside44.76% upside24.29% upside10.58% upside

Aerie Pharmaceuticals (NASDAQ:AERI) Consensus Price Target History

Price Target History for Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals (NASDAQ:AERI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2018MizuhoSet Price TargetBuy$87.00LowView Rating Details
3/5/2018Seaport Global SecuritiesReiterated RatingBuyMediumView Rating Details
3/1/2018HC WainwrightSet Price TargetBuy$78.00HighView Rating Details
2/28/2018Cantor FitzgeraldSet Price TargetBuy$86.00HighView Rating Details
1/25/2018Canaccord GenuityBoost Price TargetBuy -> Buy$73.00 -> $86.00MediumView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$80.00N/AView Rating Details
10/16/2017Needham & Company LLCReiterated RatingBuy -> Buy$65.00 -> $76.00N/AView Rating Details
10/11/2017JMP SecuritiesSet Price TargetBuy$68.00N/AView Rating Details
10/5/2017CowenReiterated RatingBuyN/AView Rating Details
7/28/2017Stifel NicolausReiterated RatingBuy$70.00MediumView Rating Details
5/25/2017AegisBoost Price TargetBuy$63.00 -> $70.00HighView Rating Details
3/9/2017Raymond JamesDowngradeStrong-Buy -> Market Perform$48.00LowView Rating Details
3/8/2017Royal Bank of CanadaBoost Price TargetOutperform$54.00 -> $55.00MediumView Rating Details
2/17/2017Roth CapitalInitiated CoverageBuy$69.00N/AView Rating Details
10/6/2016Brean CapitalReiterated RatingBuy$48.00 -> $63.00N/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Aerie Pharmaceuticals (NASDAQ:AERI) Earnings History and Estimates Chart

Earnings by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals (NASDAQ:AERI) Earnings Estimates

2018 EPS Consensus Estimate: ($3.31)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.86)($0.86)($0.86)
Q2 20181($0.82)($0.82)($0.82)
Q3 20181($0.84)($0.84)($0.84)
Q4 20181($0.79)($0.79)($0.79)

Aerie Pharmaceuticals (NASDAQ AERI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018Q4 2017($1.2110)($1.38)ViewListenView Earnings Details
11/8/2017Q3 2017($0.89)ViewN/AView Earnings Details
8/1/2017Q2 2017($0.84)($0.82)ViewListenView Earnings Details
5/2/2017Q1 2017($0.74)($0.76)ViewListenView Earnings Details
3/7/2017Q4 2016($0.67)($0.87)ViewListenView Earnings Details
11/2/2016Q316($0.70)($0.67)ViewN/AView Earnings Details
8/3/2016Q216($0.74)($0.72)ViewN/AView Earnings Details
5/2/2016Q116($0.64)($0.72)ViewN/AView Earnings Details
3/1/2016Q415($0.72)($0.64)ViewN/AView Earnings Details
11/3/2015Q315($0.66)($0.69)ViewN/AView Earnings Details
8/5/2015Q215($0.70)($0.73)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.62)($0.70)ViewListenView Earnings Details
3/2/2015Q414($0.51)($0.69)ViewN/AView Earnings Details
11/11/2014Q3 2014($0.40)($0.54)ViewN/AView Earnings Details
8/6/2014Q2 2014($0.37)($0.49)ViewN/AView Earnings Details
5/12/2014Q1 2014($0.35)($0.28)ViewN/AView Earnings Details
3/18/2014Q413($0.25)($0.62)ViewN/AView Earnings Details
12/4/2013Q313($0.25)($10.81)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Aerie Pharmaceuticals (NASDAQ:AERI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Aerie Pharmaceuticals (NASDAQ AERI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.36%
Institutional Ownership Percentage: 96.96%
Insider Trading History for Aerie Pharmaceuticals (NASDAQ:AERI)
Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals (NASDAQ AERI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/26/2017Foresite Capital Fund Ii, L.P.Major ShareholderSell20,000$55.95$1,119,000.00View SEC Filing  
4/19/2017Gerald D CagleDirectorBuy2,000$41.70$83,400.0010,900View SEC Filing  
2/15/2017Geoffrey M DuykDirectorSell41,591$46.63$1,939,388.3310,067View SEC Filing  
10/6/2016Foresite Capital Fund Ii, L.P.Major ShareholderSell50,000$40.34$2,017,000.00View SEC Filing  
7/22/2016Foresite Capital Fund Ii, L.P.Major ShareholderBuy250,000$17.50$4,375,000.00View SEC Filing  
4/15/2015Anand MehraDirectorSell425,000$33.64$14,297,000.00View SEC Filing  
1/8/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell175,000$31.11$5,444,250.00View SEC Filing  
1/5/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell23,620$30.86$728,913.20View SEC Filing  
12/29/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell80,724$30.05$2,425,756.20View SEC Filing  
12/23/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,704$30.36$1,509,013.44View SEC Filing  
12/22/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,441$30.36$1,501,028.76View SEC Filing  
11/25/2014Anand MehraDirectorSell800,000$26.00$20,800,000.00View SEC Filing  
11/25/2014Group Holdings (Sbs) Advis TpgInsiderSell1,300,000$25.97$33,761,000.00View SEC Filing  
7/10/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell1,000,000$25.17$25,170,000.00View SEC Filing  
7/9/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell500,000$25.05$12,525,000.00View SEC Filing  
5/22/2014Anand MehraDirectorSell323,932$16.00$5,182,912.00View SEC Filing  
5/22/2014Iv L.P. AcpMajor ShareholderSell300,000$16.00$4,800,000.00View SEC Filing  
5/16/2014Gerald CagleDirectorBuy1,854$15.07$27,939.781,854View SEC Filing  
10/30/2013Brian LevyInsiderBuy6,000$10.00$60,000.00View SEC Filing  
10/30/2013Iv L.P. AcpMajor ShareholderBuy110,000$10.00$1,100,000.00View SEC Filing  
10/30/2013Richard J RubinoCFOBuy10,000$10.00$100,000.00View SEC Filing  
10/30/2013Thomas A MitroCOOBuy5,000$10.00$50,000.00View SEC Filing  
10/30/2013Vicente Anido JrCEOBuy28,000$10.00$280,000.00View SEC Filing  
10/25/2013Anand MehraDirectorBuy285,000$10.00$2,850,000.00View SEC Filing  
10/25/2013Lifesciences Ii L.P. ClarusMajor ShareholderBuy321,000$10.00$3,210,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aerie Pharmaceuticals (NASDAQ AERI) News Headlines

Source:
DateHeadline
Stifel Nicolaus Raises Aerie Pharmaceuticals (AERI) Price Target to $65.00Stifel Nicolaus Raises Aerie Pharmaceuticals (AERI) Price Target to $65.00
www.americanbankingnews.com - April 19 at 11:52 PM
Critical Survey: Cellectis (CLLS) & Aerie Pharmaceuticals (AERI)Critical Survey: Cellectis (CLLS) & Aerie Pharmaceuticals (AERI)
www.americanbankingnews.com - April 18 at 11:10 PM
-$0.89 EPS Expected for Aerie Pharmaceuticals (AERI) This Quarter-$0.89 EPS Expected for Aerie Pharmaceuticals (AERI) This Quarter
www.americanbankingnews.com - April 18 at 7:08 PM
Aerie Pharmaceuticals (AERI) Upgraded to "Hold" by Zacks Investment ResearchAerie Pharmaceuticals (AERI) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 17 at 1:54 PM
Aerie Pharmaceuticals Target of Unusually High Options Trading (AERI)Aerie Pharmaceuticals Target of Unusually High Options Trading (AERI)
www.americanbankingnews.com - April 17 at 7:33 AM
Aerie Pharmaceuticals (AERI) Upgraded at Zacks Investment ResearchAerie Pharmaceuticals (AERI) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 16 at 9:17 PM
Aerie Pharmaceuticals (AERI) Raised to "Sell" at BidaskClubAerie Pharmaceuticals (AERI) Raised to "Sell" at BidaskClub
www.americanbankingnews.com - April 16 at 7:35 PM
Aerie Pharmaceuticals (AERI) "Buy" Rating Reiterated at Stifel NicolausAerie Pharmaceuticals' (AERI) "Buy" Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - April 15 at 11:35 AM
Aerie Pharmaceuticals (AERI) Given a $65.00 Price Target by Canaccord Genuity AnalystsAerie Pharmaceuticals (AERI) Given a $65.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 14 at 11:49 AM
Canaccord Genuity Analysts Give Aerie Pharmaceuticals (AERI) a $65.00 Price TargetCanaccord Genuity Analysts Give Aerie Pharmaceuticals (AERI) a $65.00 Price Target
www.americanbankingnews.com - April 12 at 11:27 AM
FDA OKs AI software to detect diabetic retinopathyFDA OKs AI software to detect diabetic retinopathy
seekingalpha.com - April 12 at 9:23 AM
Commit To Purchase Aerie Pharmaceuticals At $40, Earn 13.3% Annualized Using OptionsCommit To Purchase Aerie Pharmaceuticals At $40, Earn 13.3% Annualized Using Options
www.nasdaq.com - April 9 at 5:00 PM
Aerie Pharmaceuticals (AERI) Stock Rating Reaffirmed by MizuhoAerie Pharmaceuticals (AERI) Stock Rating Reaffirmed by Mizuho
www.americanbankingnews.com - April 8 at 2:04 PM
Aerie Pharmaceuticals (AERI) Downgraded by Zacks Investment Research to SellAerie Pharmaceuticals (AERI) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - April 7 at 5:30 PM
Aerie Pharmaceuticals (AERI) Rating Reiterated by Needham & Company LLCAerie Pharmaceuticals (AERI) Rating Reiterated by Needham & Company LLC
www.americanbankingnews.com - April 7 at 12:31 PM
Aerie Pharmaceuticals (AERI) Upgraded to "Buy" by ValuEngineAerie Pharmaceuticals (AERI) Upgraded to "Buy" by ValuEngine
www.americanbankingnews.com - April 3 at 8:10 PM
Aerie Pharmaceuticals (AERI) Up 4.6% Since Earnings Report: Can It Continue?Aerie Pharmaceuticals (AERI) Up 4.6% Since Earnings Report: Can It Continue?
finance.yahoo.com - April 2 at 9:10 AM
Zacks: Analysts Expect Aerie Pharmaceuticals Inc (AERI) to Announce -$0.89 Earnings Per ShareZacks: Analysts Expect Aerie Pharmaceuticals Inc (AERI) to Announce -$0.89 Earnings Per Share
www.americanbankingnews.com - April 1 at 7:14 PM
Aerie Pharmaceuticals Inc (AERI) Receives Consensus Rating of "Buy" from AnalystsAerie Pharmaceuticals Inc (AERI) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 1 at 3:30 PM
Aerie Pharmaceuticals (AERI) Buy Rating Reiterated at MizuhoAerie Pharmaceuticals' (AERI) Buy Rating Reiterated at Mizuho
www.americanbankingnews.com - March 31 at 8:16 PM
Mizuho Analysts Give Aerie Pharmaceuticals (AERI) a $87.00 Price TargetMizuho Analysts Give Aerie Pharmaceuticals (AERI) a $87.00 Price Target
www.americanbankingnews.com - March 29 at 6:22 PM
Aerie Pharmaceuticals (AERI) Upgraded to Hold at BidaskClubAerie Pharmaceuticals (AERI) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - March 27 at 12:06 AM
Aerie Pharmaceuticals to Present at the 17 - Business Wire (press release)Aerie Pharmaceuticals to Present at the 17 - Business Wire (press release)
www.businesswire.com - March 21 at 5:16 PM
 Brokerages Expect Aerie Pharmaceuticals Inc (AERI) Will Announce Earnings of -$0.89 Per Share Brokerages Expect Aerie Pharmaceuticals Inc (AERI) Will Announce Earnings of -$0.89 Per Share
www.americanbankingnews.com - March 15 at 3:54 PM
Aerie Pharmaceuticals to Present at the Oppenheimer & Co. 28th Annual Healthcare ConferenceAerie Pharmaceuticals to Present at the Oppenheimer & Co. 28th Annual Healthcare Conference
finance.yahoo.com - March 14 at 9:18 AM
Key events next week - healthcare (continued #3) - ACADIA ... - Seeking AlphaKey events next week - healthcare (continued #3) - ACADIA ... - Seeking Alpha
seekingalpha.com - March 10 at 8:46 AM
Aerie changes HQ to Durham, giving the Triangle another public companyAerie changes HQ to Durham, giving the Triangle another public company
finance.yahoo.com - March 8 at 6:09 PM
Seaport Global Securities Comments on Aerie Pharmaceuticals Incs Q1 2018 Earnings (AERI)Seaport Global Securities Comments on Aerie Pharmaceuticals Inc's Q1 2018 Earnings (AERI)
www.americanbankingnews.com - March 8 at 6:40 AM
Aerie Pharmaceuticals Inc (AERI) Receives Consensus Recommendation of "Buy" from BrokeragesAerie Pharmaceuticals Inc (AERI) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 7 at 3:45 PM
Aerie Pharmaceuticals (AERI) Earns Buy Rating from Seaport Global SecuritiesAerie Pharmaceuticals (AERI) Earns Buy Rating from Seaport Global Securities
www.americanbankingnews.com - March 7 at 11:00 AM
Aerie Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care ConferenceAerie Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 7 at 8:50 AM
Aerie Pharmaceuticals Inc (AERI) to Post Q2 2018 Earnings of ($0.82) Per Share, Seaport Global Securities ForecastsAerie Pharmaceuticals Inc (AERI) to Post Q2 2018 Earnings of ($0.82) Per Share, Seaport Global Securities Forecasts
www.americanbankingnews.com - March 7 at 8:45 AM
Aerie Pharmaceuticals Inc (AERI) Shares Sold by Sectoral Asset Management IncAerie Pharmaceuticals Inc (AERI) Shares Sold by Sectoral Asset Management Inc
www.americanbankingnews.com - March 5 at 4:06 PM
Aerie Pharmaceuticals Inc (AERI) Shares Bought by Senzar Asset Management LLCAerie Pharmaceuticals Inc (AERI) Shares Bought by Senzar Asset Management LLC
www.americanbankingnews.com - March 5 at 3:44 PM
Schwab Charles Investment Management Inc. Has $9.84 Million Position in Aerie Pharmaceuticals Inc (AERI)Schwab Charles Investment Management Inc. Has $9.84 Million Position in Aerie Pharmaceuticals Inc (AERI)
www.americanbankingnews.com - March 5 at 6:42 AM
State of Wisconsin Investment Board Has $1.94 Million Holdings in Aerie Pharmaceuticals Inc (AERI)State of Wisconsin Investment Board Has $1.94 Million Holdings in Aerie Pharmaceuticals Inc (AERI)
www.americanbankingnews.com - March 4 at 9:32 AM
Boulegeris Investments Inc. Has $4.20 Million Stake in Aerie Pharmaceuticals Inc (AERI)Boulegeris Investments Inc. Has $4.20 Million Stake in Aerie Pharmaceuticals Inc (AERI)
www.americanbankingnews.com - March 4 at 4:54 AM
Aerie Pharmaceuticals Inc (AERI) Position Lowered by Next Century Growth Investors LLCAerie Pharmaceuticals Inc (AERI) Position Lowered by Next Century Growth Investors LLC
www.americanbankingnews.com - March 3 at 3:53 PM
Aerie Pharmaceuticals (AERI) PT Set at $78.00 by HC WainwrightAerie Pharmaceuticals (AERI) PT Set at $78.00 by HC Wainwright
www.americanbankingnews.com - March 1 at 10:24 PM
Aeries (AERI) Q4 Loss Wider on Higher Operating ExpensesAerie's (AERI) Q4 Loss Wider on Higher Operating Expenses
www.msn.com - March 1 at 5:29 PM
Aerie's (AERI) Q4 Loss Wider on Higher Operating ExpensesAerie's (AERI) Q4 Loss Wider on Higher Operating Expenses
finance.yahoo.com - March 1 at 5:29 PM
Aerie Pharmaceuticals (AERI) Given a $86.00 Price Target by Cantor Fitzgerald AnalystsAerie Pharmaceuticals (AERI) Given a $86.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - March 1 at 11:45 AM
Aerie Pharmaceuticals (AERI) Releases  Earnings Results, Misses Expectations By $0.17 EPSAerie Pharmaceuticals (AERI) Releases Earnings Results, Misses Expectations By $0.17 EPS
www.americanbankingnews.com - March 1 at 11:38 AM
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update and 2018 GuidanceAerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update and 2018 Guidance
finance.yahoo.com - February 28 at 5:38 PM
EAM Investors LLC Trims Position in Aerie Pharmaceuticals Inc (AERI)EAM Investors LLC Trims Position in Aerie Pharmaceuticals Inc (AERI)
www.americanbankingnews.com - February 28 at 1:57 PM
Why Earnings Season Could Be Great for Aerie Pharmaceuticals (AERI)Why Earnings Season Could Be Great for Aerie Pharmaceuticals (AERI)
finance.yahoo.com - February 27 at 5:34 PM
American Century Companies Inc. Has $2.01 Million Position in Aerie Pharmaceuticals Inc (AERI)American Century Companies Inc. Has $2.01 Million Position in Aerie Pharmaceuticals Inc (AERI)
www.americanbankingnews.com - February 27 at 4:06 AM
Zacks: Brokerages Anticipate Aerie Pharmaceuticals Inc (AERI) Will Post Earnings of -$1.29 Per ShareZacks: Brokerages Anticipate Aerie Pharmaceuticals Inc (AERI) Will Post Earnings of -$1.29 Per Share
www.americanbankingnews.com - February 26 at 5:08 PM
Aerie Pharmaceuticals (AERI) Rating Lowered to Sell at BidaskClubAerie Pharmaceuticals (AERI) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - February 24 at 3:52 PM
Can Rhopressa's Approval Drive Aerie (AERI) in Q4 Earnings?Can Rhopressa's Approval Drive Aerie (AERI) in Q4 Earnings?
finance.yahoo.com - February 23 at 5:32 PM

SEC Filings

Aerie Pharmaceuticals (NASDAQ:AERI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aerie Pharmaceuticals (NASDAQ:AERI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aerie Pharmaceuticals (NASDAQ AERI) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.